Mairs and Power's ABT Position Overview
Mairs and Power (via Mairs & Power INC) currently holds 722.9K shares of Abbott Laboratories (ABT) worth $96.82 M, representing 0.91% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Mairs and Power has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2017, adding 2.9M shares. Largest reduction occurred in Q2 2019, reducing 520.6K shares.
Analysis based on 13F filings available since 2013 Q2
Mairs and Power's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Mairs and Power
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +324,841 | Add 0.00% | 324,840 | $34.88 |
| Q3 2013 | +14,021 | Add 4.32% | 338,861 | $33.19 |
| Q4 2013 | +12,512 | Add 3.69% | 351,373 | $38.33 |
| Q1 2014 | -7,508 | Reduce 2.14% | 343,865 | $38.51 |
| Q2 2014 | +24,943 | Add 7.25% | 368,808 | $40.90 |
| Q3 2014 | -8,838 | Reduce 2.40% | 359,970 | $41.59 |
| Q4 2014 | -3,151 | Reduce 0.88% | 356,819 | $45.02 |
| Q1 2015 | -3,095 | Reduce 0.87% | 353,724 | $46.33 |
| Q2 2015 | -11,886 | Reduce 3.36% | 341,838 | $49.08 |
| Q3 2015 | -22,495 | Reduce 6.58% | 319,343 | $40.22 |
| Q4 2015 | -425 | Reduce 0.13% | 318,918 | $44.91 |
| Q1 2016 | +473 | Add 0.15% | 319,391 | $41.83 |
| Q2 2016 | +87,093 | Add 27.27% | 406,484 | $39.31 |
| Q3 2016 | +683,078 | Add 168.05% | 1.09 M | $42.29 |
| Q4 2016 | +243,474 | Add 22.35% | 1.33 M | $38.41 |
| Q1 2017 | +2.94 M | Add 220.39% | 4.27 M | $44.41 |
| Q2 2017 | +257,647 | Add 6.03% | 4.53 M | $48.61 |
| Q3 2017 | +41,700 | Add 0.92% | 4.57 M | $53.36 |
| Q4 2017 | -26,869 | Reduce 0.59% | 4.54 M | $57.07 |
| Q1 2018 | -286,016 | Reduce 6.30% | 4.26 M | $59.92 |
| Q2 2018 | -412,021 | Reduce 9.68% | 3.85 M | $60.99 |
| Q3 2018 | -408,755 | Reduce 10.63% | 3.44 M | $73.36 |
| Q4 2018 | -269,098 | Reduce 7.83% | 3.17 M | $72.33 |
| Q1 2019 | -156,850 | Reduce 4.95% | 3.01 M | $79.94 |
| Q2 2019 | -520,626 | Reduce 17.29% | 2.49 M | $84.10 |
| Q3 2019 | -154,768 | Reduce 6.22% | 2.34 M | $83.67 |
| Q4 2019 | -382,866 | Reduce 16.40% | 1.95 M | $86.86 |
| Q1 2020 | -202,919 | Reduce 10.39% | 1.75 M | $78.91 |
| Q2 2020 | -158,646 | Reduce 9.07% | 1.59 M | $91.43 |
| Q3 2020 | -107,916 | Reduce 6.78% | 1.48 M | $108.83 |
| Q4 2020 | -21,959 | Reduce 1.48% | 1.46 M | $109.49 |
| Q1 2021 | -9,497 | Reduce 0.65% | 1.45 M | $119.84 |
| Q2 2021 | +55,536 | Add 3.83% | 1.51 M | $115.93 |
| Q3 2021 | +1,702 | Add 0.11% | 1.51 M | $118.13 |
| Q4 2021 | -9,087 | Reduce 0.60% | 1.5 M | $140.74 |
| Q1 2022 | -36,370 | Reduce 2.43% | 1.46 M | $118.36 |
| Q2 2022 | -15,657 | Reduce 1.07% | 1.45 M | $108.65 |
| Q3 2022 | -9,380 | Reduce 0.65% | 1.44 M | $96.76 |
| Q4 2022 | -106,272 | Reduce 7.39% | 1.33 M | $109.79 |
| Q1 2023 | -12,948 | Reduce 0.97% | 1.32 M | $101.26 |
| Q2 2023 | -15,333 | Reduce 1.16% | 1.3 M | $109.02 |
| Q3 2023 | -4,640 | Reduce 0.36% | 1.3 M | $96.85 |
| Q4 2023 | -13,538 | Reduce 1.04% | 1.29 M | $110.07 |
| Q1 2024 | -35,788 | Reduce 2.78% | 1.25 M | $113.66 |
| Q2 2024 | -156,877 | Reduce 12.55% | 1.09 M | $103.91 |
| Q3 2024 | -7,367 | Reduce 0.67% | 1.09 M | $114.01 |
| Q4 2024 | -8,514 | Reduce 0.78% | 1.08 M | $113.11 |
| Q1 2025 | -59,927 | Reduce 5.56% | 1.02 M | $132.65 |
| Q2 2025 | -115,047 | Reduce 11.31% | 901,941 | $136.01 |
| Q3 2025 | -179,057 | Reduce 19.85% | 722,884 | $133.94 |
Mairs and Power's Abbott Laboratories Investment FAQs
Mairs and Power first purchased Abbott Laboratories (ABT) in Q2 2013, acquiring 324,840 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power has held Abbott Laboratories (ABT) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power's largest addition to Abbott Laboratories (ABT) was in Q1 2017, adding 4,270,907 shares worth $189.67 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Mairs and Power's firm, Mairs & Power INC, owns 722,884 shares of Abbott Laboratories (ABT), valued at approximately $96.82 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Abbott Laboratories (ABT) represents approximately 0.91% of Mairs and Power's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power's peak holding in Abbott Laboratories (ABT) was 4,570,254 shares, as reported at the end of Q3 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.